Johnson & JohnsonJNJ
JNJ
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
117% more first-time investments, than exits
New positions opened: 228 | Existing positions closed: 105
22% more call options, than puts
Call options by funds: $3.21B | Put options by funds: $2.62B
15% more funds holding in top 10
Funds holding in top 10: 163 [Q2] → 188 (+25) [Q3]
8% more capital invested
Capital invested by funds: $261B [Q2] → $281B (+$20.1B) [Q3]
2% more funds holding
Funds holding: 3,734 [Q2] → 3,806 (+72) [Q3]
2.22% less ownership
Funds ownership: 73.93% [Q2] → 71.72% (-2.22%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 1,519 | Existing positions reduced: 1,703
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$152
4%
upside
Avg. target
$167
14%
upside
High target
$190
29%
upside
10 analyst ratings
5 positive
50%
5 neutral
50%
0 negative
0%
RBC Capital Shagun Singh 54% 1-year accuracy 37 / 69 met price target | 23%upside $181 | Outperform Reiterated | 23 Jan 2025 |
Morgan Stanley Terence Flynn 38% 1-year accuracy 6 / 16 met price target | 11%upside $163 | Equal-Weight Maintained | 23 Jan 2025 |
Stifel Rick Wise 70% 1-year accuracy 21 / 30 met price target | 6%upside $155 | Hold Maintained | 23 Jan 2025 |
Leerink Partners David Risinger 20% 1-year accuracy 2 / 10 met price target | 15%upside $169 | Outperform Maintained | 23 Jan 2025 |
Wells Fargo Larry Biegelsen 66% 1-year accuracy 31 / 47 met price target | 4%upside $152 | Equal-Weight Maintained | 23 Jan 2025 |
Financial journalist opinion
Based on 144 articles about JNJ published over the past 30 days
Neutral
Accesswire
11 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson("J&J" or the "Company") (NYSE:JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
MarketBeat
1 day ago
Why Traders Are Buying the Dip on Johnson & Johnson Stock
It is no secret that the defensive names in the stock market today, the ones not known for their hot price action or wild return potential, have been the lackluster segment of the financial markets lately. This is because the center of attention has been taken by the technology sector and some of the darling names in that space for all of 2023 and 2024.
Negative
The Motley Fool
1 day ago
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024
The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the market, since its components' performance is indicative of what's happening in the economy and the markets.
Positive
Invezz
1 day ago
Best 5 dividend aristocrat stocks to buy and hold
Dividend aristocrats, or companies that have paid and raised dividends for at least 25 years are some of the best value stocks to buy and hold. Many of them have solid balance sheets and a long record of doing well for their share holders.
Neutral
Accesswire
2 days ago
JNJ ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Johnson & Johnson
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.
Neutral
Accesswire
2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ
NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson("J&J" or the "Company") (NYSE:JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
2 days ago
Johnson & Johnson Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - JNJ
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Johnson & Johnson ("Johnson & Johnson") (NYSE:JNJ) concerning possible violations of federal securities laws. J&J issued a press release on January 8, 2025, announcing that "on January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE™ cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation.
Neutral
Accesswire
2 days ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Johnson & Johnson (JNJ) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Johnson & Johnson ("J&J" or "the Company") (NYSE:JNJ). Investors who purchased J&J securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/JNJ.
Positive
Forbes
2 days ago
What's Next For JNJ Stock After An Upbeat Q4?
Johnson & Johnson (NYSE: JNJ) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates of $22.4 billion and $2.02, respectively.
Positive
The Motley Fool
2 days ago
5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025
With thousands of publicly traded companies and exchange-traded funds (ETFs) to choose from, Wall Street offers countless ways for investors to grow their wealth. Though there's no one-size-fits-all blueprint to make bank, buying and holding high-quality dividend stocks has a favorable track record of delivering for investors.
Charts implemented using Lightweight Charts™